The viral protein of SARS-COV-2 called SPIKE links through its binding domain to the ACE2 receptor located on many human cells. This allows the virus to enter the cells. Researchers then performed mutations on the SPIKE binding domain and most of them alter the expression of the binding domain and its binding to ACE2. This study therefore identified regions…
GEG-tech signs Distribution Agreement with tebu-bio GEG-tech’s agreement with tebu-bio expands the distribution of advanced vectorisation systems & tools, designed by GEG-tech (genetic engineering lab) into the European Market. GEG-tech, the technology leader in advanced lentiviral vectorisation systems, announces a distribution agreement with tebu-bio to bolster its coverage of the…
Innovation in cancerology: meeting in Monaco GEG Tech will be attending the 14th Biennale Monegasque de Cancerologie. It will take place at the end on Januray 2020 in Monaco. More than 1300 participants will be gathering and discussing the evolution and progresses of cancerology. Various themes will be discussed, among…
Gene therapy : an extensive overview Recent advances in the field of genetic engineering are expanding the capability of gene therapy to treat diseases, notably those previously unreachable. As a proof, the last two years saw the number of marketing authorization for gene therapy products significantly rise. Last month, Novartis…
CAR-Based Immunotherapy We would like to share some exciting results on CAR-Based Immunotherapy. It comes from our partner Dr Oana Gavriliuc from OncoGen “Victor Babes” University of Medicine and Pharmacy, Timisoara (Romania). We are proud to introduce the poster presented by Dr Gavriliuc at the ICLE 2019 (London). The poster titled CAR-Based…
These past few months, cancer immunotherapy has sped-up thanks to CAR technology. One look at the recent news about this is enough to figure that out. As examples: Two major deals between pharmaceutical companies and biotechs specialized in CAR T-cells: Gilead bought Kite Pharma for $12 billion, and Celgene bought Juno Therapeutics…
ANCHOR Technology / Partnership We are proud to annonce you that GEG Tech has validated the combination of the ANCHOR technology developed by NeoVirTech with our Lenti-ONE vectors. This breakthrough technology allowed us to generate the first auto-fluorescent lentiviral vectors for live imaging and screening applications. For more details about the new possibilities offered by…
First-ever live tracking of HIV-1 based lentiviral vectors in human cells Technology breakthrough: visualization of lentivirus genomes in living cells using ANCHOR technology. We are proud to announce that we obtain great results through a collaborative project with NeoVirTech, a company developing auto fluorescent virus for imaging and screening applications….
The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes In this article, Merienne et al. designed a smart lentiviral vector system to improve the safety for genome editing of CNS disease gene. They characterized their CRISPR self-inactivating system (KamiCas9) for permanent disruption of huntingtin gene in the context…
Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder resulting from a polyglutamine expansion in the huntingtin (HTT) protein. There is currently no cure for this disease, but recent studies suggest that RNAi to downregulate the expression of both normal and…
